Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

NEOVACS :2018 Financial Calendar

Posted on: 16 Feb 18


2018 Financial Calendar

Paris, February 16, 2018, 6pm CET - NEOVACS (Euronext Growth Paris : ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, annonced today its financial reporting calendar for 2018.

Financial publications will be released prior to the opening of the Paris stock exchange. This calendar is indicative and subject to change.

  • Shareholders AGM- 1 st convocation                                                                 February 28, 2018
  • Shareholders AGM - 2 nd convocation                                                               March 12, 2018
  • 2017 Full-Year Results                                                                                      March 30, 2018
  • Shareholders'  Annual General Assembly- 1 st convocation                              May 15, 2018
  • Shareholders'  Annual General Assembly- 2 nd   convocation                            May 28, 2018
  • 2018 Half-Year Results                                                                                     October 30, 2018

About Neovacs
Listed on Euronext Growth since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by four patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNalpha Kinoid, an immunotherapy being developed for the indication of lupus, dermatomyositis and also in preclinical trial for Type 1 diabetes. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases.


NEOVACS - Corporate Communication & Investor Relations
Charlène Masson
+33 (0)1 53 10 93 00

LIFE SCIENCE ADVISORS- Investor Relations / Financial Communications
Chris Maggos       


Press release

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: NEOVACS via GlobeNewswire

Last updated on: 18/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.